1.5.2007
News

International agreement to eliminate customs duties on approved pharmaceuticals

EU Member States adopted an international agreement to eliminate customs dutieson all new pharmaceuticals traded with the US and Switzerland. The agreement wasreached on 12 January 2007 and eliminates customs duties between the EU,Switzerland and US on finished pharmaceutical products and on the chemicalintermediates used in their production. It replaces a previous agreement from1994 that already enabled many pharmaceuticals to benefit from zero-tariffs, butdid not cover any of the more recent products. With this review, 1,290additional products have been added to the 7,329 products currently benefitingfrom duty-free treatment. The EU imports more than 80% of its pharmaceuticalsfrom the US and Switzerland, and the European Chemical Industry Council (CEFIC)believes that the agreement could save European pharmaceutical companies up to€230 million in 2007 alone.

Other articles

1.4.2025
News

We Succeeded in Another International Ranking

Just a week after the results of the Chambers Europe ranking were announced, we’re thrilled to share more great news – the renowned Legal 500 has published its annual overview of the leading law firms in the EMEA region, and we have once again confirmed our strong market position.
26.3.2025
News

We Confirmed Our Strong Standing in the Chambers Europe Rankings

We are pleased to announce that we have confirmed last year’s strongest-ever results in the Chambers Europe rankings, published by Chambers & Partners. In the 2025 edition, KŠB once again received excellent rankings in 11 categories. In addition, 13 of our colleagues received individual recognition—our best result in the firm’s history. This year’s recognition is crowned by a nomination for the prestigious Chambers Europe Awards 2025 for the best law firm in the Czech Republic.
5.3.2025
News

First Commentary on the Bonds Act Published

C.H. Beck has released the first-ever commentary on the Bonds Act, authored primarily by KŠB’s Jan Lasák, Jan Dědič, and Josef Kříž. Spanning over 700 pages, this comprehensive publication provides an in-depth interpretation of the Act’s individual provisions, drawing on the authors’ extensive expertise in corporate finance